LabCorp 2008 Annual Report Download - page 7

Download and view the complete annual report

Please find page 7 of the 2008 LabCorp annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 58

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58

Determines the right drug
and the
right dose
Companion Diagnostics
What works for one person may not work for another.
Enter companion diagnostics, an integral component of
personalized medicine and a fi eld that is changing the
way in which drug therapies and treatment are delivered.
At its simplest level, companion diagnostics provides
guidance on administering the proper drug to the proper
patient at the proper dose. Increasingly, patients will fi nd
that just what the doctor ordered is tailor-made for them.
Laboratory Corporation of America® Holdings 2008 5
K-ras Mutation Analysis
Survival rates for those with
metastatic colorectal cancer are
improving, thanks to new combina-
tions of existing chemotherapies and
the introduction of targeted therapies.
Many of these therapies, however,
are associated with increased toxicity
and clinical response, and resistance
varies among patients. LabCorp’s
recently introduced K-ras Mutation
Analysis provides a predictive clinical
biomarker to help physicians deter-
mine which patients are best suited
for specifi c new therapies. For those
battling this deadly disease, knowing
what will work, and what will not, can
be life-saving intelligence.